ChartRow logo
Data provided bySource: Twelve Data
SMMT
$10.67-9.73%
as of close, Nov 17, 2026
☾ AH $10.67 -9.73%
PeersBBIOBNTXASNDARGXGHPRAX
Share this page

SMMT SEC filings (2026)

CIK 1599298 · Pharmaceutical Preparations (SIC 2834) · fiscal year ends in December

568 filings on EDGAR since 2014 · 13 annual, 19 quarterly, 245 current · financial statements · earnings

Latest 10-K
Feb 23, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Nov 4, 2026
quarter to Sep 30, 2026
Latest 8-K
Nov 16, 2026
Other events
Last earnings release
Nov 4, 2026
−$0.26 vs −$0.28 · ▼ 12.2%
Filings on file
568
since 2014, 133 insider forms

What happened, last 12 months#

Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.

November 2026

October 2026

September 2026

August 2026

July 2026

June 2026

April 2026

February 2026

January 2026

Insider transactions#

What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.

Over the last 13 months insiders sold nothing and bought $103.6M in 5 purchases; 16 other transactions (awards, exercises, tax withholding, gifts and plan purchases).

DateInsider
Jun 12, 2026Form 4DUGGAN ROBERT WCo-Chief Executive Officer · Director · 10% ownerBought · $50.0M · 3,810,000 sh
Jun 12, 2026Form 4Zanganeh MahkamCo-Chief Executive Officer · Director · 10% ownerBought · $50.0M · 3,810,000 sh
Jun 4, 2026Form 4DUGGAN ROBERT WCo-Chief Executive Officer · Director · 10% ownerBought · $1.5M · 100,000 sh
Jun 4, 2026Form 4Zanganeh MahkamCo-Chief Executive Officer · Director · 10% ownerBought · $1.5M · 100,000 sh
Jun 4, 2026Form 4Soni Manmeet SinghCOO and CFO · DirectorBought · $722K · 50,000 sh
Awards, exercises, withholding and plan purchases · 16 transactions
DateInsider
Nov 16, 2026Form 4DUGGAN ROBERT WCo-Chief Executive Officer · Director · 10% ownerExercise or conversion · $530K · 500,000 sh
Nov 16, 2026Form 4Zanganeh MahkamCo-Chief Executive Officer · Director · 10% ownerExercise or conversion · $530K · 500,000 sh
Nov 16, 2026Form 4Soni Manmeet SinghCOO and CFO · DirectorExercise or conversion · $137K · 100,000 sh
Nov 16, 2026Form 4DUGGAN ROBERT WCo-Chief Executive Officer · Director · 10% ownerExercise or conversion · Stock Option (right to buy) · $0 · 500,000 sh
Nov 16, 2026Form 4Zanganeh MahkamCo-Chief Executive Officer · Director · 10% ownerExercise or conversion · Stock Option (right to buy) · $0 · 500,000 sh
Nov 16, 2026Form 4Soni Manmeet SinghCOO and CFO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 100,000 sh
Oct 8, 2026Form 4Anand BhaskarChief Accounting OfficerAward · $0 · 100,000 sh
Jan 8, 2026Form 4Anand BhaskarChief Accounting OfficerAward · Stock Option (right to buy) · — · 30,000 sh
Jan 2, 2026Form 4Clark Kenneth ADirectorAward · Stock Option (right to buy) · $156K+ · 52,796 sh
Jan 2, 2026Form 4DUGGAN ROBERT WCo-Chief Executive Officer · Director · 10% ownerAward · Stock Option (right to buy) · $98K · 11,232 sh
Jan 2, 2026Form 4Zanganeh MahkamCo-Chief Executive Officer · Director · 10% ownerAward · Stock Option (right to buy) · $98K · 11,232 sh
Jan 2, 2026Form 4Huber JeffDirectorAward · Stock Option (right to buy) · $87K+ · 44,885 sh
Jan 2, 2026Form 4Booth Robert F.DirectorAward · Stock Option (right to buy) · $63K+ · 42,180 sh
Jan 2, 2026Form 4Cesano AlessandraDirectorAward · Stock Option (right to buy) · $28K+ · 38,219 sh
Jan 2, 2026Form 4Ronaghi MostafaDirectorAward · Stock Option (right to buy) · — · 35,000 sh
Jan 2, 2026Form 4Xia YuDirectorAward · Stock Option (right to buy) · — · 35,000 sh

Reports and proxy statements#

Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.

2026 · 30 filings
FiledWhat it is
Nov 16, 20268-KOther events
Nov 4, 20268-KOther events
Nov 4, 202610-QQuarterly report, Q3 2026 — net income −$208.4M, EPS −$0.26
Nov 4, 20268-KEarnings release — EPS −$0.26 vs −$0.28 est. (+7.1%) 12.2%
Oct 19, 2026DEF 14AProxy statement
Oct 6, 2026PRE 14APreliminary proxy statement
Sep 29, 20268-KAstraZeneca Makes $2 Billion Strategic Equity Investment in Summit TherapeuticsMaterial definitive agreement; Unregistered sale of equity; Charter, bylaws or fiscal-year change; Other events
Sep 15, 20268-KOther events
Sep 14, 20268-KOther events
Sep 3, 20268-KOther events
Aug 26, 20268-KOther events
Aug 5, 20268-KOther events
Jul 23, 20268-KMaterial definitive agreement
Jul 23, 202610-QQuarterly report, Q2 2026 — net income −$215.7M, EPS −$0.28
Jul 23, 20268-KEarnings release — EPS −$0.28 vs −$0.26 est. (−7.7%) 8.8%
Jul 22, 20268-KOther events
Jun 12, 20268-KShareholder vote results
Jun 11, 20268-KRegulation FD disclosure
Jun 3, 20268-KOther events
Jun 1, 20268-KOther events
Apr 30, 202610-QQuarterly report, Q1 2026 — net income −$189.4M, EPS −$0.24
Apr 30, 20268-KEarnings release — EPS −$0.24 vs −$0.33 est. (+27.3%) 24.9%
Apr 17, 2026DEFA14AAdditional proxy materials
Apr 17, 2026ARSAnnual report to shareholders
Apr 17, 2026DEF 14AProxy statement
Apr 6, 2026PRE 14APreliminary proxy statement
Feb 23, 202610-KAnnual report, FY2025 — net income −$1.08B, EPS −$1.44
Feb 23, 20268-KEarnings release — EPS −$0.29 vs −$0.22 est. (−31.8%) 0.2%
Jan 29, 20268-KOther events
Jan 12, 20268-KResults of operations; Regulation FD disclosure
2025 · 21 filings
FiledWhat it is
Nov 7, 20258-KOther events
Oct 22, 20258-KSummit Therapeutics Raises $500 Million in Private PlacementMaterial definitive agreement; Unregistered sale of equity; Regulation FD disclosure
Oct 20, 202510-QQuarterly report, Q3 2025 — net income −$231.8M, EPS −$0.31
Oct 20, 20258-KEarnings release — EPS −$0.31 vs −$0.14 est. (−121.4%) 4.5%
Sep 8, 20258-KOther events
Aug 11, 20258-KEarnings release — EPS −$0.76 vs −$0.10 est. (−660.0%) 9.1%
Aug 11, 20258-KMaterial definitive agreement
Aug 11, 202510-QQuarterly report, Q2 2025 — net income −$565.7M, EPS −$0.76
Jun 20, 20258-KMaterial definitive agreement
Jun 17, 20258-KShareholder vote results
May 30, 20258-KOther events
May 1, 202510-QQuarterly report, Q1 2025 — net income −$62.9M, EPS −$0.09
May 1, 20258-KEarnings release — EPS −$0.09 vs −$0.10 est. (+10.0%) 13.1%
Apr 29, 2025ARSAnnual report to shareholders
Apr 29, 2025DEF 14AProxy statement
Apr 25, 20258-KOther events
Apr 23, 20258-KOther events
Feb 24, 202510-KAnnual report, FY2024 — revenue $0, net income −$221.3M, EPS −$0.31
Feb 24, 20258-KEarnings release — EPS −$0.08 vs −$0.08 est.; revenue $0 14.8%
Jan 24, 20258-KDirectors or officers; compensation; Other events
Jan 13, 20258-KResults of operations; Regulation FD disclosure
2024 · 28 filings
FiledWhat it is
Oct 30, 202410-QQuarterly report, Q3 2024 — revenue $0, net income −$56.3M, EPS −$0.08
Oct 30, 20248-KEarnings release — EPS −$0.08 vs −$0.07 est. (−14.3%); revenue $0 14.6%
Sep 12, 20248-KMaterial definitive agreement; Unregistered sale of equity; Regulation FD disclosure
Sep 9, 20248-KRegulation FD disclosure; Other events
Aug 6, 202410-QQuarterly report, Q2 2024 — net income −$60.4M, EPS −$0.09
Aug 6, 20248-KEarnings release — EPS −$0.05 vs −$0.06 est. (+16.7%) 4.7%
Jun 27, 20248-KMaterial definitive agreement; Directors or officers; compensation
Jun 17, 20248-KDirectors or officers; compensation; Shareholder vote results
Jun 13, 2024DEFA14AAdditional proxy materials
Jun 3, 20248-KMaterial definitive agreement; Unregistered sale of equity; Regulation FD disclosure
Jun 3, 20248-KRegulation FD disclosure; Other events
May 30, 20248-KOther events
May 24, 20248-KOther events
May 13, 20248-KMaterial definitive agreement
May 1, 20248-KEarnings release — EPS −$0.05 vs −$0.06 est. (+16.7%) 19.6%
May 1, 202410-QQuarterly report, Q1 2024 — net income −$43.5M, EPS −$0.06
Apr 25, 2024DEF 14AProxy statement
Apr 11, 20248-KDirectors or officers; compensation
Apr 3, 20248-KDirectors or officers; compensation
Mar 22, 20248-KOther events
Mar 12, 20248-KRegulation FD disclosure
Mar 5, 20248-KOther events
Feb 20, 20248-KEarnings release — EPS −$0.05; revenue $0 26.2%
Feb 20, 202410-KAnnual report, FY2023 — revenue $0 (−100% y/y), net income −$614.9M, EPS −$0.99
Feb 15, 20248-KRegulation FD disclosure
Feb 8, 20248-KOther events
Jan 8, 20248-KResults of operations; Regulation FD disclosure
Jan 3, 20248-KOther events
2023 · 26 filings — 19 × 8-K, 3 × 10-Q, 2 × DEF 14A and 2 other forms
FiledWhat it is
Nov 7, 202310-QQuarterly report, Q3 2023 — revenue $0 (−100% y/y), net income −$21.3M, EPS −$0.03
Sep 19, 2023DEF 14AProxy statement
Sep 8, 2023PRE 14APreliminary proxy statement
Aug 9, 202310-QQuarterly report, Q2 2023 — revenue $0 (−100% y/y), net income −$14.7M, EPS −$0.02
May 11, 202310-QQuarterly report, Q1 2023 — revenue $0 (−100% y/y), net income −$542.4M, EPS −$1.43
Apr 21, 2023DEF 14AProxy statement
Mar 9, 202310-KAnnual report, FY2022 — revenue $705K (−61% y/y), net income −$78.8M, EPS −$0.41

19 current reports (8-K) not listed; the year is on EDGAR.

2022 · 36 filings — 25 × 8-K, 3 × 10-Q, 3 × DEF 14A and 4 other forms
FiledWhat it is
Dec 21, 202210-K/AAnnual report, amended
Dec 13, 2022DEF 14AProxy statement
Nov 29, 2022PRE 14APreliminary proxy statement
Nov 9, 202210-QQuarterly report, Q3 2022 — revenue $220K (−83% y/y), net income −$21.4M, EPS −$0.10
Aug 11, 202210-QQuarterly report, Q2 2022 — revenue $235K (+312% y/y), net income −$16.8M, EPS −$0.12
Jul 6, 2022DEF 14AProxy statement
Jun 24, 2022PRE 14APreliminary proxy statement
Jun 3, 2022DEFA14AAdditional proxy materials
May 11, 202210-QQuarterly report, Q1 2022 — revenue $250K (+30% y/y), net income −$21.4M, EPS −$0.15
Apr 29, 2022DEF 14AProxy statement
Mar 17, 202210-KAnnual report

25 current reports (8-K) not listed; the year is on EDGAR.

2021 · 26 filings — 20 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
FiledWhat it is
Nov 15, 202110-QQuarterly report, Q3 2021 — revenue $1.3M (+623% y/y), net income −$19.6M, EPS −$0.20
Aug 12, 202110-QQuarterly report, Q2 2021 — revenue $57K (−66% y/y), net income −$24.4M, EPS −$0.27
Jun 2, 2021DEFA14AAdditional proxy materials
May 17, 202110-QQuarterly report, Q1 2021 — revenue $192K (−41% y/y), net income −$17.5M, EPS −$0.21
Apr 29, 2021DEF 14AProxy statement
Mar 31, 202110-KAnnual report, FY2020 — revenue $860K (+16% y/y), net income −$52.7M, EPS −$0.76

20 current reports (8-K) not listed; the year is on EDGAR.

2020 · 30 filings — 20 × 6-K, 7 × 8-K, 1 × 10-Q and 2 other forms
FiledWhat it is
Nov 16, 202010-QQuarterly report, Q3 2020 — revenue $181K (+22% y/y), net income −$17.7M, EPS −$0.26
Apr 30, 202020-FAnnual report (foreign private issuer), FY2019 — revenue $743K (−99% y/y), net income −$29.1M, EPS −$0.89

28 current reports (8-K) not listed; the year is on EDGAR.

2019 · 18 filings — 16 × 6-K, 1 × 20-F, 1 × 6-K/A
FiledWhat it is
Mar 29, 201920-FAnnual report (foreign private issuer), FY2018 — revenue $57.1M (+255% y/y), net income $10.9M, EPS $0.63

17 current reports (8-K) not listed; the year is on EDGAR.

2018 · 22 filings — 21 × 6-K, 1 × 20-F
FiledWhat it is
Apr 13, 201820-FAnnual report (foreign private issuer), FY2017 — revenue $16.1M (+423% y/y), net income −$26.2M, EPS −$0.40

21 current reports (8-K) not listed; the year is on EDGAR.

2017 · 20 filings — 19 × 6-K, 1 × 20-F
FiledWhat it is
Mar 30, 201720-FAnnual report (foreign private issuer)

19 current reports (8-K) not listed; the year is on EDGAR.

2016 · 19 filings — 18 × 6-K, 1 × 20-F

Counted, not listed; the year is on EDGAR.

2015 · 22 filings — 21 × 6-K, 1 × 20-F

Counted, not listed; the year is on EDGAR.

Insider, ownership and other filings#

Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.

2026 · 26 filings — 18 × 4, 2 × 424B5, 2 × UPLOAD and 4 other forms
FiledWhat it is
Nov 16, 20264Insider transaction (Form 4)
Nov 16, 20264Insider transaction (Form 4)
Nov 16, 20264Insider transaction (Form 4)
Nov 4, 2026424B7Registration and prospectus
Oct 14, 20264Insider transaction (Form 4)
Jul 23, 2026424B5Prospectus supplement
Jun 12, 20264Insider transaction (Form 4)
Jun 12, 20264Insider transaction (Form 4)
Jun 10, 2026424B5Prospectus supplement
Jun 9, 2026S-3ASRAutomatic shelf registration
Jun 4, 20264Insider transaction (Form 4)
Jun 4, 20264Insider transaction (Form 4)
Jun 4, 20264Insider transaction (Form 4)
Apr 27, 2026UPLOADLetter from the SEC staff
Apr 16, 2026CORRESPLetter to the SEC
Apr 2, 2026UPLOADLetter from the SEC staff
Feb 23, 2026S-8Employee stock plan registration
Jan 12, 20264Insider transaction (Form 4)
Jan 6, 20264Insider transaction (Form 4)
Jan 6, 20264Insider transaction (Form 4)
Jan 6, 20264Insider transaction (Form 4)
Jan 6, 20264Insider transaction (Form 4)
Jan 6, 20264Insider transaction (Form 4)
Jan 6, 20264Insider transaction (Form 4)
Jan 6, 20264Insider transaction (Form 4)

The newest 25 of 26 shown; the full year is on EDGAR.

2025 · 30 filings — 25 × 4, 1 × 424B5, 1 × CORRESP and 3 other forms
FiledWhat it is
Oct 29, 2025S-3ASRAutomatic shelf registration
Oct 23, 20254Insider transaction (Form 4)
Oct 23, 20254Insider transaction (Form 4)
Oct 23, 20254Insider transaction (Form 4)
Oct 23, 20254Insider transaction (Form 4)
Oct 23, 20254Insider transaction (Form 4)
Sep 19, 20254Insider transaction (Form 4)
Sep 11, 20254Insider transaction (Form 4)
Sep 11, 20254Insider transaction (Form 4)
Aug 11, 2025424B5Prospectus supplement
Jun 2, 20254Insider transaction (Form 4)
Jun 2, 20254Insider transaction (Form 4)
May 19, 2025S-8Employee stock plan registration
May 1, 20254Insider transaction (Form 4)
May 1, 20254Insider transaction (Form 4)
May 1, 20254Insider transaction (Form 4)
May 1, 20254Insider transaction (Form 4)
Apr 9, 20254Insider transaction (Form 4)
Apr 9, 20254Insider transaction (Form 4)
Jan 21, 2025UPLOADLetter from the SEC staff
Jan 14, 20254Insider transaction (Form 4)
Jan 6, 20254Insider transaction (Form 4)
Jan 6, 20254Insider transaction (Form 4)
Jan 6, 20254Insider transaction (Form 4)
Jan 6, 20254Insider transaction (Form 4)

The newest 25 of 30 shown; the full year is on EDGAR.

2024 · 37 filings — 21 × 4, 3 × 3, 2 × D and 9 other forms
FiledWhat it is
Dec 19, 2024UPLOADLetter from the SEC staff
Oct 15, 20244Insider transaction (Form 4)
Oct 3, 20244Insider transaction (Form 4)
Sep 26, 2024DOther filings
Sep 19, 2024S-3ASRAutomatic shelf registration
Sep 13, 20244Insider transaction (Form 4)
Sep 13, 20244Insider transaction (Form 4)
Sep 13, 2024SC 13D/AActive holder above 5% (Schedule 13D), amended
Sep 13, 20244Insider transaction (Form 4)
Sep 13, 20244Insider transaction (Form 4)
Sep 13, 20244Insider transaction (Form 4)
Aug 23, 20244Insider transaction (Form 4)
Aug 23, 20244Insider transaction (Form 4)
Aug 6, 2024S-3ASRAutomatic shelf registration
Jun 27, 20244Insider transaction (Form 4)
Jun 27, 20243Initial insider holdings (Form 3)
Jun 18, 2024DOther filings
May 13, 2024424B5Prospectus supplement
May 1, 2024S-8Employee stock plan registration
Apr 15, 20244Insider transaction (Form 4)
Apr 15, 20243Initial insider holdings (Form 3)
Apr 4, 20244Insider transaction (Form 4)
Apr 4, 20244Insider transaction (Form 4)
Apr 4, 20243Initial insider holdings (Form 3)
Mar 27, 20244Insider transaction (Form 4)

The newest 25 of 37 shown; the full year is on EDGAR.

2023 · 28 filings — 12 × 4, 3 × CORRESP, 2 × 4/A and 8 other forms

Counted, not listed; the year is on EDGAR.

2022 · 25 filings — 14 × 4, 3 × 3, 2 × CT ORDER and 5 other forms

Counted, not listed; the year is on EDGAR.

2021 · 27 filings — 12 × 4, 4 × 3, 3 × SC 13D/A and 7 other forms

Counted, not listed; the year is on EDGAR.

2020 · 39 filings — 10 × 3, 8 × SC 13D/A, 7 × 4 and 10 other forms

Counted, not listed; the year is on EDGAR.

2019 · 12 filings — 3 × SC 13D/A, 1 × 424B3, 1 × CORRESP and 7 other forms

Counted, not listed; the year is on EDGAR.

2018 · 10 filings — 4 × CT ORDER, 1 × CORRESP, 1 × EFFECT and 4 other forms

Counted, not listed; the year is on EDGAR.

2017 · 6 filings — 2 × 424B5, 2 × CT ORDER, 1 × SC 13D/A and 1 other form

Counted, not listed; the year is on EDGAR.

2016 · 8 filings — 2 × CT ORDER, 1 × CORRESP, 1 × EFFECT and 4 other forms

Counted, not listed; the year is on EDGAR.

2015 · 19 filings — 3 × UPLOAD, 2 × CORRESP, 2 × EFFECT and 11 other forms

Counted, not listed; the year is on EDGAR.

2014 · 3 filings — 1 × D, 1 × DRS, 1 × UPLOAD

Counted, not listed; the year is on EDGAR.

About this data#

Summit Therapeutics Inc. Common Stock (SMMT) has 568 filings on EDGAR going back to 2014: 13 annual reports, 19 quarterly reports and 245 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 23, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Nov 16, 2026, covered other events. Over the last 13 months insiders sold nothing and bought $103.6M in 5 purchases; 16 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.

Every row is a filing EDGAR lists for the registrants that have been Summit Therapeutics Inc. Common Stock, read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.

FAQ#

Where can I read SMMT's latest 10-K?
SMMT's latest annual report, a 10-K, was filed on Feb 23, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
When did SMMT last file an 8-K?
On Nov 16, 2026 it covered other events. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Nov 4, 2026.
Are SMMT insiders buying or selling?
Over the last 13 months insiders sold nothing and bought $103.6M in 5 purchases; 16 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
How many SEC filings has SMMT made?
568 filings are on EDGAR under the registrant records that have been Summit Therapeutics Inc. Common Stock, going back to 2014; 133 of them are insider ownership forms (Forms 3, 4, 5 and 144).